These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9306403)

  • 1. Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization.
    Gerloni M; Baliou WR; Billetta R; Zanetti M
    Nat Biotechnol; 1997 Sep; 15(9):876-81. PubMed ID: 9306403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VH and VL region structure of antibodies that recognize the (NANP)3 dodecapeptide sequence in the circumsporozoite protein of Plasmodium falciparum.
    Anker R; Zavala F; Pollok BA
    Eur J Immunol; 1990 Dec; 20(12):2757-61. PubMed ID: 2125276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.
    Triller G; Scally SW; Costa G; Pissarev M; Kreschel C; Bosch A; Marois E; Sack BK; Murugan R; Salman AM; Janse CJ; Khan SM; Kappe SHI; Adegnika AA; Mordmüller B; Levashina EA; Julien JP; Wardemann H
    Immunity; 2017 Dec; 47(6):1197-1209.e10. PubMed ID: 29195810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against Plasmodium falciparum challenge induced in Aotus monkeys by liver-stage antigen-3-derived long synthetic peptides.
    Perlaza BL; Valencia AZ; Zapata C; Castellanos A; Sauzet JP; Blanc C; Cohen J; Arévalo-Herrera M; Corradin G; Herrera S; Druilhe P
    Eur J Immunol; 2008 Sep; 38(9):2610-5. PubMed ID: 18792413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards a synthetic malaria vaccine: cyclization of a peptide eliminates the production of parasite-unreactive antibody.
    Etlinger HM; Trzeciak A
    Philos Trans R Soc Lond B Biol Sci; 1993 Apr; 340(1291):69-72. PubMed ID: 8099745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes.
    Xiong S; Gerloni M; Zanetti M
    Nat Biotechnol; 1997 Sep; 15(9):882-6. PubMed ID: 9306404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durable immunity and immunologic memory to a parasite antigen induced by somatic transgene immunization.
    Gerloni M; Xiong S; Zanetti M
    Vaccine; 1998; 16(2-3):293-7. PubMed ID: 9607045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
    Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
    Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines.
    Del Giudice G; Cooper JA; Merino J; Verdini AS; Pessi A; Togna AR; Engers HD; Corradin G; Lambert PH
    J Immunol; 1986 Nov; 137(9):2952-5. PubMed ID: 3531341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
    Bergmann ES; Ballou RW; Krzych U
    Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys.
    Rodríguez A; Mintardjo R; Tax D; Gillissen G; Custers J; Pau MG; Klap J; Santra S; Balachandran H; Letvin NL; Goudsmit J; Radosević K
    Vaccine; 2009 Oct; 27(44):6226-33. PubMed ID: 19686691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The antibody response in BALB/c mice to the Plasmodium falciparum circumsporozoite repetitive epitope covalently coupled to synthetic lipopeptide adjuvant.
    Wiesmüller KH; Jung G; Gillessen D; Loffl C; Bessler WG; Böltz T
    Immunology; 1991 Jan; 72(1):109-13. PubMed ID: 1705236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of antibodies to Plasmodium falciparum sporozoites by employing synthetic peptides.
    Del Giudice G; Biro S; Degrémont AA; Engers HD; Lambert PH; Pessi A; Tougne C; Verdini AS; Weiss N; Tanner M
    Parassitologia; 1986; 28(2-3):107-11. PubMed ID: 3332303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
    Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
    J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
    Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
    Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.
    Singh S; Soe S; Mejia JP; Roussilhon C; Theisen M; Corradin G; Druilhe P
    J Infect Dis; 2004 Sep; 190(5):1010-8. PubMed ID: 15295710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria.
    Dodoo D; Theisen M; Kurtzhals JA; Akanmori BD; Koram KA; Jepsen S; Nkrumah FK; Theander TG; Hviid L
    J Infect Dis; 2000 Mar; 181(3):1202-5. PubMed ID: 10720556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.